Neuroendocrine cell differentiation in the CWR22 human prostate cancer xenograft: Association with tumor cell proliferation prior to recurrence

No abstract is available for this paper.

• Publication year

  2004

• Venue

  The Prostate

• Publication date

  2004-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/pros.20032PMID 15162375
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pathobiology of autochthonous prostate cancer in a pre‐clinical transgenic mouse model

  2003cited by this paper
• Neuroendocrine differentiation in human prostate tissue: is it detectable and treatable?

  2003cited by this paper
• Synergistic activation of the androgen receptor by bombesin and low-dose androgen.

  2002cited by this paper
• Androgen receptor expression and cellular proliferation during transition from androgen-dependent to recurrent growth after castration in the CWR22 prostate cancer xenograft.

  2002cited by this paper
• Metastatic prostate carcinoma to bone

  2002cited by this paper
• Different profiles of neuroendocrine cell differentiation evolve in the PC‐310 human prostate cancer model during long‐term androgen deprivation

  2002cited by this paper
• A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.

  2001cited by this paper
• Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen.

  2001cited by this paper
• Multipathways for transdifferentiation of human prostate cancer cells into neuroendocrine-like phenotype.

  2001cited by this paper
• Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments.

  2001cited by this paper
• Prognostic significance of neuroendocrine differentiation, proliferation activity and androgen receptor expression in prostate cancer

  2001cited by this paper
• Relationship between neuroendocrine features and prognostic parameters in human prostate adenocarcinoma.

  2001cited by this paper
• Neuroendocrine pathogenesis in adenocarcinoma of the prostate.

  2001cited by this paper
• Immunohistochemical analysis of the proliferative activity of neuroendocrine tumors from various organs

  2000cited by this paper
• Correlation between neovascularisation and neuroendocrine differentiation in prostatic carcinoma.

  2000cited by this paper
• Prognostic Significance of Neuroendocrine Differentiation in Prostate Cancer

  2000cited by this paper
• STAT3 mediates IL‐6‐induced neuroendocrine differentiation in prostate cancer cells

  2000cited by this paper
• Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment

  2000cited by this paper
• Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression.

  1999cited by this paper
• Kinetics of neuroendocrine differentiation in an androgen-dependent human prostate xenograft model.

  1999cited by this paper
• Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo.

  1999cited by this paper
• Receptors for BPH growth factors are located in some neuroendocrine cells

  1998cited by this paper
• Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes.

  1998cited by this paper
• Prostatic neuroendocrine cells have a unique keratin expression pattern and do not express Bcl-2: cell kinetic features of neuroendocrine cells in the human prostate.

  1997cited by this paper
• Neuroendocrine stains and proliferative indices of prostatic adenocarcinomas in transurethral resection samples.

  1997cited by this paper
• Neuroendocrine cells in non-endocrine tumors: what does it mean?

  1997cited by this paper
• Transdifferentiation of cultured human prostate cancer cells to a neuroendocrine cell phenotype in a hormone-depleted medium.

  1997cited by this paper
• CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar.

  1996influential reference
• P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo.

  1996cited by this paper
• Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells.

  1996cited by this paper
• Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells.

  1995cited by this paper
• CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma.

  1994influential reference
• BCL-2 proto-oncogene expression in prostate cancer and its relationship to the prostatic neuroendocrine cell.

  1994cited by this paper
• Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP.

  1994cited by this paper
• Neuroendocrine differentiation in metastatic prostatic adenocarcinoma.

  1994cited by this paper
• The androgen receptor status of neuroendocrine cells in human benign and malignant prostatic tissue.

  1993cited by this paper
• Relation of endocrine‐paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate

  1991cited by this paper
• Basal cell carcinomas grown in nude mice produce and deposit fibronectin in the extracellular matrix.

  1986cited by this paper

• PlexinD1 is a driver and a therapeutic target in advanced prostate cancer

  2025cites this paper
• Neuropilin-2 promotes lineage plasticity and progression to neuroendocrine prostate cancer

  2022cites this paper
• Comparative study of neuroendocrine acquisition and biomarker expression between neuroendocrine and usual prostatic carcinoma

  2021cites this paper
• WLS-Wnt signaling promotes neuroendocrine prostate cancer

  2021cites this paper
• Zeb1 and SK3 Channel Are Up-Regulated in Castration-Resistant Prostate Cancer and Promote Neuroendocrine Differentiation

  2021cites this paper
• Serotonin Pathway in Cancer

  2021cites this paper
• Reduced NCOR2 expression accelerates androgen deprivation therapy failure in prostate cancer

  2020cites this paper
• The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications

  2018cites this paper
• AR AND CgA in situ DETECTION AS PROGNOSTIC CLINICAL MARKERS IN PROSTATE ADENOCARCINOMA

  2018cites this paper
• EMT, stemness and tumor plasticity in aggressive variant neuroendocrine prostate cancers.

  2018cites this paper
• Lineage plasticity-mediated therapy resistance in prostate cancer

  2018cites this paper
• Biology and evolution of poorly differentiated neuroendocrine tumors

  2017cites this paper
• Characterization of fibroblast‐free CWR‐R1ca castration‐recurrent prostate cancer cell line

  2016cites this paper
• Elucidation of AR impact on the paternally expressed Gene 10 (PEG10) in Enzalutamide-resistant prostate cancer

  2016cites this paper
• Isoform 1 of TPD52 (PC-1) promotes neuroendocrine transdifferentiation in prostate cancer cells

  2016cites this paper
• Icaritin suppresses development of neuroendocrine differentiation of prostate cancer through inhibition of IL-6/STAT3 and Aurora kinase A pathways in TRAMP mice.

  2016cites this paper
• Alterations of androgen receptor-regulated enhancer RNAs (eRNAs) contribute to enzalutamide resistance in castration-resistant prostate cancer

  2016cites this paper
• Carboplatin-etoposide combination chemotherapy in metastatic castration-resistant prostate cancer: A retrospective study

  2015cites this paper
• Tissue Chromogranin A Expression during Prostate Cancer Progression: Prediction of Chemosensitivity.

  2015cites this paper
• Neuroendocrine Differentiation in Prostate Cancer: A Mechanism of Radioresistance and Treatment Failure

  2015cites this paper
• Serotonin and cancer: what is the link?

  2015cites this paper
• Androgen-Targeted Therapy-Induced Epithelial Mesenchymal Plasticity and Neuroendocrine Transdifferentiation in Prostate Cancer: An Opportunity for Intervention

  2014cites this paper
• Models of neuroendocrine prostate cancer.

  2014cites this paper
• Neuroendocrine differentiation of prostate cancer.

  2013cites this paper
• Xenograft, Transgenic, and Knockout Models of Prostate Cancer

  2013cites this paper
• Neuroendocrine differentiation does not have independent prognostic value in conservatively treated prostate cancer

  2012cites this paper
• Tumor Suppressor Function of PGP9.5 Is Associated with Epigenetic Regulation in Prostate Cancer—Novel Predictor of Biochemical Recurrence after Radical Surgery

  2012cites this paper
• Neuroendocrine Differentiation in the Progression of Prostate Cancer: An Update on Recent Developments

  2012cites this paper
• LNCaP prostate cancer cells with autocrine interleukin‐6 expression are resistant to IL‐6‐induced neuroendocrine differentiation due to increased expression of suppressors of cytokine signaling

  2012cites this paper
• The Raf/MEK/extracellular signal-regulated kinase 1/2 pathway can mediate growth inhibitory and differentiation signaling via androgen receptor downregulation in prostate cancer cells.

  2011cites this paper
• Platinum Agents in Prostate Cancer

  2010cites this paper
• Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors.

  2010cites this paper
• The Siah2-HIF-FoxA2 axis in prostate cancer – new markers and therapeutic opportunities

  2010cites this paper
• Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails

  2010cites this paper
• Neuroendocrine differentiation in prostate cancer.

  2009cites this paper
• Oct4A is expressed by a subpopulation of prostate neuroendocrine cells

  2009cites this paper
• Oncogenic activation of androgen receptor.

  2009cites this paper
• Cellular and molecular signatures of androgen ablation of prostate cancer

  2009cites this paper
• Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer

  2009cites this paper
• The relationship of neuroendocrine carcinomas to anti‐tumor therapies in TRAMP mice

  2009cites this paper
• Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features.

  2009cites this paper
• Inappropriate activation of androgen receptor by relaxin via β-catenin pathway

  2008cites this paper
• Inappropriate activation of androgen receptor by relaxin via beta-catenin pathway.

  2008cites this paper
• Neuroendocrine Differentiation in Prostate Cancer: From Lab to Bedside

  2007cites this paper
• Clinical implications of neuroendocrine differentiation in prostate cancer

  2007cites this paper
• Function and molecular mechanisms of neuroendocrine cells in prostate cancer.

  2007cites this paper
• Is there a role for platinum chemotherapy in the treatment of patients with hormone‐refractory prostate cancer?

  2007cites this paper
• Biphasic effect of androgens on prostate cancer cells and its correlation with androgen receptor coactivator dopa decarboxylase.

  2007cites this paper
• Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells.

  2007cites this paper
• Immunohistochemical characterization of neuroendocrine cells in prostate cancer

  2006influential citation
• Genistein‐induced neuroendocrine differentiation of prostate cancer cells

  2006cites this paper
• Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer.

  2006cites this paper
• EVALUATION OF NEUROENDOCRINE AND PROLIFERATIVE MARKERS IN PROSTATIC ADENOCARCINOMAS

  2006cites this paper
• Phosphatidylinositol 3-Kinase-AKT-Mammalian Target of Rapamycin Pathway Is Essential for Neuroendocrine Differentiation of Prostate Cancer*

  2006cites this paper
• Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells.

  2006cites this paper
• Protocadherin‐PC promotes androgen‐independent prostate cancer cell growth

  2006cites this paper
• Protein tyrosine phosphatase PTP1B is involved in neuroendocrine differentiation of prostate cancer

  2006cites this paper
• Neuroendocrine differentiation in prostate cancer

  2005cites this paper
• Protein C inhibitor (plasminogen activator inhibitor-3) expression in the CWR22 prostate cancer xenograft.

  2005cites this paper
• Interferon‐γ induces neuroendocrine‐like differentiation of human prostate basal‐epithelial cells

  2005cites this paper